Clinical Trial Update: Dose Individualization of Pemetrexed - IMPROVE-I [Phase 4]

View source ↗

Summary

This report provides an update on the Phase 4 IMPROVE-I trial evaluating dose individualization of pemetrexed in non-small cell lung cancer and mesothelioma; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed (pemetrexed)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Non Small Cell Lung Cancer, Mesothelioma | Phase 4 | Status: COMPLETED